NEW YORK (GenomeWeb) – Shuwen Biotech announced today that it has received CE-IVD marking for its real-time PCR-based EGFR detection kit for lung cancer.

According to the company, the kit detects 29 mutations in exons 18, 19, 20, and 21, and has a limit of mutation detection at .1 percent in a background of wild-type DNA. It also contains lyophilized reagents that can withstand at least 12 freeze/thaw cycles.

With the CE-IVD marking, the kit is now approved for sale throughout the European Economic Area.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.